These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19890185)

  • 1. Cost-effectiveness of HIV interventions: from cohort studies and clinical trials to policy.
    Walensky RP
    Top HIV Med; 2009; 17(4):130-4. PubMed ID: 19890185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanded screening for HIV in the United States--an analysis of cost-effectiveness.
    Paltiel AD; Weinstein MC; Kimmel AD; Seage GR; Losina E; Zhang H; Freedberg KA; Walensky RP
    N Engl J Med; 2005 Feb; 352(6):586-95. PubMed ID: 15703423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness of combination antiretroviral therapy for HIV disease.
    Freedberg KA; Losina E; Weinstein MC; Paltiel AD; Cohen CJ; Seage GR; Craven DE; Zhang H; Kimmel AD; Goldie SJ
    N Engl J Med; 2001 Mar; 344(11):824-31. PubMed ID: 11248160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical impact and cost-effectiveness of routine, voluntary HIV screening in South Africa.
    Walensky RP; Wood R; Fofana MO; Martinson NA; Losina E; April MD; Bassett IV; Morris BL; Freedberg KA; Paltiel AD;
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):26-35. PubMed ID: 21068674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
    Pinkerton SD; Holtgrave DR; Pinkerton HJ
    Arch Intern Med; 1997 Sep; 157(17):1972-80. PubMed ID: 9308509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.
    Desai K; Sansom SL; Ackers ML; Stewart SR; Hall HI; Hu DJ; Sanders R; Scotton CR; Soorapanth S; Boily MC; Garnett GP; McElroy PD
    AIDS; 2008 Sep; 22(14):1829-39. PubMed ID: 18753932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs.
    Paltiel AD; Walensky RP; Schackman BR; Seage GR; Mercincavage LM; Weinstein MC; Freedberg KA
    Ann Intern Med; 2006 Dec; 145(11):797-806. PubMed ID: 17146064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
    Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE
    AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy.
    Sanders GD; Bayoumi AM; Sundaram V; Bilir SP; Neukermans CP; Rydzak CE; Douglass LR; Lazzeroni LC; Holodniy M; Owens DK
    N Engl J Med; 2005 Feb; 352(6):570-85. PubMed ID: 15703422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness.
    Weinstein MC; Goldie SJ; Losina E; Cohen CJ; Baxter JD; Zhang H; Kimmel AD; Freedberg KA
    Ann Intern Med; 2001 Mar; 134(6):440-50. PubMed ID: 11255519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.
    Kauf TL; Farkouh RA; Earnshaw SR; Watson ME; Maroudas P; Chambers MG
    Pharmacoeconomics; 2010; 28(11):1025-39. PubMed ID: 20575592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals.
    Kühne FC; Chancellor J; Mollon P; Myers DE; Louie M; Powderly WG
    HIV Clin Trials; 2010; 11(2):80-99. PubMed ID: 20542845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in Côte d'Ivoire: A model-based analysis.
    Ouattara EN; MacLean RL; Danel C; Borre ED; Gabillard D; Huang M; Moh R; Paltiel AD; Eholié SP; Walensky RP; Anglaret X; Freedberg KA
    PLoS One; 2019; 14(6):e0219068. PubMed ID: 31247009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.
    Corzillius M; Mühlberger N; Sroczynski G; Jaeger H; Wasem J; Siebert U
    Antivir Ther; 2004 Feb; 9(1):27-36. PubMed ID: 15040534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How HIV treatment advances affect the cost-effectiveness of prevention.
    Pinkerton SD; Holtgrave DR
    Med Decis Making; 2000; 20(1):89-94. PubMed ID: 10638541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of genotypic antiretroviral resistance testing in HIV-infected patients with treatment failure.
    Sendi P; Günthard HF; Simcock M; Ledergerber B; Schüpbach J; Battegay M;
    PLoS One; 2007 Jan; 2(1):e173. PubMed ID: 17245449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using information on ART costs and benefits to mobilise resources - comparing different methods and contexts.
    Kinghorn A
    Afr J AIDS Res; 2019 Dec; 18(4):289-296. PubMed ID: 31779574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term benefits of genotypic resistance testing in patients with extensive prior antiretroviral therapy: a model-based approach.
    Yazdanpanah Y; Vray M; Meynard J; Losina E; Weinstein MC; Morand-Joubert L; Goldie SJ; Hsu HE; Walensky RP; Dalban C; Sax PE; Girard PM; Freedberg KA
    HIV Med; 2007 Oct; 8(7):439-50. PubMed ID: 17760736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.